Companies › Vega Therapeutics
1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 1; Hematology; next expected readout Oct 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| VGA039 Von Willebrand Factor (VWF) mimetic or modulator | – | Phase 3 | Von Willebrand Disease (VWD); Von Willebrand Diseases | Oct 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07115004 | VGA039 | Phase 3 | Von Willebrand Disease (VWD) | Hematology | Oct 2028 |
| NCT05776069 | VGA039 | Phase 1 | Von Willebrand Diseases | Hematology | Dec 2029 |
No annotated target.
–
Pharmanutra VarmX MIBIO PTE. Bioverativ, a Sanofi company Hangzhou Gensciences Biopharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.